WUXI BIOLOGICS
WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseases worldwide.
WUXI BIOLOGICS
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
2014-01-01
Status:
Active
Contact:
+86 (510)-8183-1205
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Auris Medical
Auris Medical develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Shaymaa Taieb
Shaymaa Taieb Associate Director, upstream Continious Manufacturing @ WuXi Biologics Associate Director, upstream Continious Manufacturing 2019-08-01
Weichang Zhou
Weichang Zhou Chief Technology Officer & Executive Vice President @ WuXi Biologics Chief Technology Officer & Executive Vice President
Christine Lu-Wong
Christine Lu-Wong Chief Financial Officer & Executive Vice President @ WuXi Biologics Chief Financial Officer & Executive Vice President
Zhisheng Chen
Zhisheng Chen Chief Executive Officer @ WuXi Biologics Chief Executive Officer 2016-01-01
Stock Details
Company's stock symbol is HKG:2269
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2021-03-17 | CMAB BioPharm | CMAB BioPharm acquired by WuXi Biologics | N/A |
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2021-05-19 | Duality Biologics | WuXi Biologics investment in Series B - Duality Biologics | 90 M USD |
2020-09-30 | Invetx | WuXi Biologics investment in Series A - Invetx | 10.25 M USD |
2020-02-24 | Invetx | WuXi Biologics investment in Series A - Invetx | 15 M USD |
2019-05-21 | Inhibrx | WuXi Biologics investment in Convertible Note - Inhibrx | 40 M USD |
2019-04-23 | Duoning Biotech | WuXi Biologics investment in Series A - Duoning Biotech | 100 M CNY |